Taken together, our results indicate that the dysregulation of miR-193a-3p is involved in the tumorigenesis of colorectal cancer, particularly BRAF-mutant cancer, and is likely to affect drug sensitivities to anti-EGFR therapy in colorectal cancer regardless of BRAF mutational status. The gene discussed is EGFR; the disease is cancer.